CARs and TRUCKs: Driving a Paradigm Shift in Hematologic Malignancies

Authors

Christine Charek, South College; University of Lynchburg DMSc alumFollow
Tia Solh, South University; University of Lynchburg DMSc candidateFollow

Specialty

Medical Sciences; Hematology/Oncology

Advisor

Drs. Mark Archambault/Laura Witte/Jenna Rolfs

Abstract

Hematologic malignancies account for a significant number of annual cancer diagnoses and deaths across the globe. Historically, the prognosis for relapsed and/or refractory disease after standard therapies, such as chemotherapy and/or radiation, was poor. Chimeric antigen receptor (CAR) T-cell therapy offers an additional treatment option. While promising, this type of immunotherapy also comes with potentially severe side effects, toxicities, and limitations. A better understanding of the development, administration, and management of patients undergoing treatment can provide the general clinician with the knowledge to assist within a multidisciplinary team to ultimately improve patient outcomes.

Recommended Citation

Charek, Christine and Solh, Tia (2025) "CARs and TRUCKs: Driving a Paradigm Shift in Hematologic Malignancies," Lynchburg Journal of Medical Science: Vol. 1: Iss. 2, Article 21.
DOI: https://doi.org/10.63932/3067-7106.1028
Available at: https://digitalshowcase.lynchburg.edu/jms/vol1/iss2/21